Scipio bioscience has been selected by the @European Innovation Council for a €2.5M grant to pursue their efforts toward the next generation of single-cell tools
We are delighted to announce our selection by the @European Innovation Council for a €2.5M grant to pursue our efforts toward the next generation of single-cell tools. We are honored to be trusted by the EIC accelerator program to deliver innovative scientific solutions for the near future. This grant also comes with a commitment from the EIC to participate in our next funding round with €4M of investment. This grant will allow us to accelerate the development of the next generation of our single-cell technology. This follows the launch last month of Asteria, our first single-cell RNA-seq kit, and Cytonaut, its companion data analysis software. Our current solution provides access to single-cell sequencing with unrivaled ease and will drive its adoption throughout life science research. The second generation will be a leap forward in both performance and versatility and deliver a range of tools empowering all life scientists to advance knowledge and improve human health.
The EU is thus investing in precision medicine of the future. Our technology will allow scientists to look more deeply into individual cells and deliver personalised healthcare. This scientific leap will be pivotal in treatment of diseases like cancer, where current technologies and medicines fall short of dealing with the ever-diverse needs of patients.
We at Scipio bioscience are committed to drive the expansion of single-cell sequencing, with the belief that our technology is the key to unlocking the path for diagnostics and therapeutics desperately needed for illnesses difficult to treat.
About the EIC: The European Innovation Council is Europe’s €10.1B flagship innovation programme, with a unique funding system based on a combination of grants and equity investment awarded to start-ups and SMEs through a highly competitive selection process.
